DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Axenfeld-Rieger syndrome type 3 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAxenfeld-Rieger syndrome type 3 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for axenfeld-rieger syndrome type 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
collagen type IV alpha 1 chain (COL4A1) — COL4A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5NAY · 1.8 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Axenfeld-Rieger syndrome type 3 is a rare autosomal dominant condition with genetic and morphologic variability. The main causative gene is PITX2 at 4q25, and mutations range from point mutations to microscopic or submicroscopic deletions. In two unrelated patients diagnosed with Rieger syndrome, cytogenetically invisible submicroscopic deletions at 4q25 were identified; one patient had a translocation with a deletion at the 4q breakpoint, the other an interstitial deletion, and both deletions included only the PITX2 and ENPEP genes. A separate study of a novel L130F missense mutation in FOXC1, found in two patients, showed that the mutant protein was expressed at levels similar to wild-type but migrated at a reduced apparent molecular weight, suggesting differential phosphorylation. The L130F protein had a significantly impaired capacity to localise to the nucleus, bind DNA, and transactivate reporter genes, demonstrating that helix 3 of the forkhead domain is important for FOXC1 function.
Ocular manifestations include posterior embryotoxon, iris and anterior angle abnormalities with a high risk of glaucoma and blindness. Systemic manifestations include craniofacial anomalies such as maxillary hypoplasia, hypodontia, oligodontia and microdontia. Two case reports describe a 7-year-old female and a 5-year-old child with ARS who presented with significant ocular and dental anomalies; the 7-year-old was also found to have osteopenia. Both reports describe the dental condition, immediate treatment, and long-term treatment needs, but neither provides quantitative outcomes such as survival or response rates.
No clinical trials, no drug interventions, and no quantitative efficacy data are reported in these abstracts. What is still missing are any clinical trials testing treatments, any patient stratification by genetic subtype, and any funding directed toward developing or repurposing drugs for this condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Special Care in Dentistry · 2010 · 26 citations
ARTICLE: Axenfeld-Rieger Syndrome (ARS): A review and case report
AbstractAxenfeld-Rieger syndrome (ARS) is a rare, autosomal dominant condition characterized by ocular, craniofacial, dental, and periumbilical abnormalities. Relatively little information exists on this syndrome within the dental literature despite the fact that midface hypoplasia and maxillary hypodontia are classical presenting features of this syndrome. This is a case report of a 7-year-old Caucasian female with ARS who presented with significant ocular and dental anomalies. She was also found to have osteopenia. Her dental condition is described, her immediate treatment is shown, and her long-term treatment needs are discussed.
AbstractAxenfeld-Rieger syndrome (ARS) is a genetically heterogeneous autosomal dominant disorder mainly characterized by developmental defects of the anterior segment and extraocular anomalies. ARS shows great clinical variability and encompasses several conditions with overlapping phenotypes, including Rieger syndrome (RS). RS is characterized by developmental defects of the eyes, teeth and umbilicus, and the main causative gene is PITX2 (paired-like homeodomain transcription factor 2, or RIEG1) at 4q25. PITX2 mutations show great variety, from point mutations to microscopic or submicroscopic deletions, and apparently balanced translocations in few cases. We identified cytogenetically undetectable submicroscopic deletions at 4q25 in two unrelated patients diagnosed with RS. One patient had a t(4;17)(q25;q22)dn translocation with a deletion at the 4q breakpoint, and the other patient had an interstitial deletion of 4q25. Both deletions included only the PITX2 and ENPEP (glutamyl aminopeptidase) genes.
Analyses of a Novel L130F Missense Mutation in FOXC1
AbstractOBJECTIVE: To understand how the novel L130F mutation, found in 2 patients with Axenfeld-Rieger syndrome, disrupts function of the forkhead box C1 protein (FOXC1). METHODS: Sequencing DNA from patients with Axenfeld-Rieger syndrome identified a novel missense mutation that results in an L130F substitution in the FOXC1 gene. Site-directed mutagenesis was used to introduce the L130F mutation into the FOXC1 complementary DNA. The level of L130F protein expression was determined by means of immunoblotting. We determined the mutant protein's ability to localize to the nucleus, bind DNA, and transactivate a reporter construct. RESULTS: The FOXC1 L130F mutant protein is expressed at levels similar to those of wild-type FOXC1. The L130F protein, however, migrated at an apparent reduced molecular weight compared with the wild-type protein, suggesting that the mutant and wild-type proteins may be differentially phosphorylated. The L130F protein also had a significantly impaired capacity to localize to the nucleus, bind DNA, and transactivate reporter genes. CONCLUSIONS: The disease-causing L130F mutation further demonstrates that helix 3 of the forkhead domain is important for the FOXC1 protein to properly localize to the nucleus, bind DNA, and activate gene expression. CLINICAL RELEVANCE: The inability of FOXC1 to function owing to the L130F mutation provides further insight into how disruptions in the FOXC1 gene lead to human Axenfeld-Rieger syndrome.
Korean Journal of Ophthalmology · 2015 · 9 citations · open access
A Family with Axenfeld-Rieger Syndrome: Report of the Clinical and Genetic Findings
AbstractPURPOSE: To describe clinical findings in a Korean family with Axenfeld-Rieger syndrome. METHODS: A retrospective review of clinical data about patients with diagnosed Axenfeld-Rieger syndrome. Five affected members of the family underwent a complete ophthalmologic examination. We screened the forkhead box C1 gene and the pituitary homeobox 2 gene in patients. Peripheral blood leukocytes and buccal mucosal epithelial cells were obtained from seven members of a family with Axenfeld-Rieger syndrome. DNA was extracted and amplified by polymerase chain reaction, followed by direct sequencing. RESULTS: The affected members showed iris hypoplasia, iridocorneal adhesions, posterior embryotoxon, and advanced glaucoma in three generation. None had systemic anomalies. Two mutations including c.1362_1364insCGG and c.1142_1144insGGC were identified in forkhead box C1 in four affected family members. CONCLUSIONS: This study may help to understand clinical findings and prognosis for patients with Axenfeld-Rieger syndrome.
Saudi Journal of Oral Sciences · 2019 · 0 citations · open access
Dental and craniofacial anomalies associated with Axenfeld–Rieger syndrome
AbstractAxenfeld–Rieger syndrome (ARS) is a rare, autosomal dominant disorder with genetic and morphologic variability and characterized by ocular and nonocular clinical findings. Midface hypoplasia and maxillary hypodontia are classical presenting features of this syndrome. This case report describes a dental condition, immediate treatment required and a long-term treatment approach toward a patient 5-year-of-age with ARS, who presented with significant ocular and dental anomalies.
Journal of Ophthalmology Research Reviews & Reports · 2021 · 0 citations · open access
Axenfeld-Rieger Syndrome: A Case Report with Literature Review
AbstractAxenfeld–Rieger syndrome (ARS) is a rare autosomal dominant disorder that has both systemic and ocular anterior segment dysgenesis. The ocular manifestations include posterior embryotoxon, iris and anterior angle abnomalies with a high risk of glaucoma and blindness. The systemic manifestations can include craniofacial abnomalies such as maxillary hypoplasia, hypodontia, oligodontia and microdont.
International Journal of Innovative Technologies in Social Science · 2025 · 0 citations · open access
DIAGNOSIS AND TREATMENT OF AXENFELD-RIEGER SYNDROME
AbstractIntroduction: Axenfeld-Rieger syndrome (ARS) is a rare congenital disorder characterized by anterior segment dysgenesis and diverse systemic anomalies. Mutations in genes such as PITX2 and FOXC1 are most commonly implicated in its pathogenesis. The condition significantly affects vision, primarily due to structural disruption of the visual axis and the high incidence of secondary glaucoma. Aim of the study: The purpose of this study is to provide an updated overview of Axenfeld-Rieger syndrome, with emphasis on its historical background, genetic mechanisms, clinical manifestations, and current therapeutic strategies. Research materials and methods: A systematic review of scientific and medical literature was conducted using PubMed and Google Scholar databases. Conclusions: Genetic testing and comprehensive clinical evaluation are crucial for accurate diagnosis and optimal management of ARS. Due to its multisystem nature, care should be coordinated within a multidisciplinary framework. Early recognition of glaucoma and other systemic manifestations is essential to improve long-term outcomes.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
